Liver metastases showdown: radiation vs. microwave ablation in new trial
NCT ID NCT03654131
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two minimally invasive treatments—microwave ablation and stereotactic body radiation therapy—for colorectal cancer that has spread to the liver. About 100 patients with 1 to 3 liver tumors that cannot be surgically removed will be randomly assigned to one of the two treatments. The goal is to see which approach better controls tumor growth in the liver and has fewer side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
100 people
The number who actually took part.
- Started
-
Jul 2018
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Colorectal cancer patients with oligo metastatic disease in the liver (1 to 3 tumors), and where metastases are found unsuitable for resection because of 1. non-resectability 2. small metastasis localized deep in the liver, where a parenchyma sparing intervention is preferred over an extensive resection 3. previous extensive liver surgery 4. comorbidity 2. The multidisciplinary team should all agree that both percutaneous or open surgical MW-ablation and SBRT are safe as first treatment choice for the individual patient. 3. Tumor sizes ≤4.0 cm 4. Age \> 18 years 5. Signed informed consent Exclusion Criteria: 1. Previous radiotherapy to the liver 2. Liver volume \< 700 ml 3. Another active cancer disease within the past 36 months 4. Not able to understand written or oral protocol information
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Righospitalet
Copenhagen, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a lab test tell which chemo works for colon cancer?
- Can MRI and computer models predict how well cancer drugs reach tumors?
- Gut bacteria may hold clues to why some cancer treatments work better
- Burning the edges: a new way to stop colon polyps from coming back
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?
- Can zapping liver and lung tumors boost treatment for nasopharyngeal cancer?